IRWD
Ironwood Pharmaceuticals, Inc.NASDAQHealthcare$3.54-0.28%ClosedMarket Cap: $577.2M
As of 2026-04-06
Valuation
P/E (TTM)
24.03
PEG
0.01
P/B
-2.19
P/S
1.94
EV/EBITDA
7.83
DCF Value
$7.10
FCF Yield
22.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.6%
Operating Margin
33.2%
Net Margin
8.1%
ROE
-8.2%
ROA
6.1%
ROIC
9.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $47.7M | 99.0% | $6.6M | $-2.3M | $-0.01 | — |
| FY 2025 | $296.2M | 99.4% | $118.8M | $24.0M | $0.15 | — |
| Q3 2025 | $122.1M | 100.0% | $75.5M | $40.1M | $0.23 | — |
| Q2 2025 | $85.2M | 100.0% | $45.3M | $23.6M | $0.14 | — |
| Q1 2025 | $41.1M | 33.3% | $-29.1M | $-37.4M | $-0.23 | — |
| Q4 2024 | $90.5M | 100.0% | $31.5M | $2.3M | $0.01 | — |
| FY 2024 | $351.4M | 97.9% | $93.1M | $880.0K | $0.01 | — |
| Q3 2024 | $91.6M | 67.4% | $25.6M | $3.6M | $0.02 | — |
| Q2 2024 | $94.4M | 100.0% | $25.0M | $-860.0K | $-0.01 | — |
| Q1 2024 | $74.9M | 65.5% | $11.0M | $-4.2M | $-0.03 | — |
| Q4 2023 | $117.6M | 100.0% | $37.6M | $-1.1M | $-0.01 | — |
| FY 2023 | $442.7M | 98.6% | $-945.4M | $-1.00B | $-6.45 | — |